Halozyme Therapeutics Inc (HALO)

Halozyme Therapeutics Inc (HALO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $14.3B; returns 1 day +0.9%, 1 week +3.1%, 1 year +87.8%.

Halozyme Therapeutics, Inc. (HALO) is a biopharmaceutical company focused on developing and commercializing drug delivery technologies. Its primary revenue driver is the ENHANZE® technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable drugs, biologics, and fluids, which would otherwise require intravenous administration.

Groups HALO belongs to

• Shrinking Share Count
• Biotechnology
• Royalty Streams
• Healthcare
• Biopharmaceutical
• Drug Discovery
• Biologics
• Commercial Stage Biotech
• Life Sciences
• Commercial Stage

HALO financial model: income statement, cash flow and balance sheet